CA3173732A1 - Gpr40 agonists - Google Patents
Gpr40 agonistsInfo
- Publication number
- CA3173732A1 CA3173732A1 CA3173732A CA3173732A CA3173732A1 CA 3173732 A1 CA3173732 A1 CA 3173732A1 CA 3173732 A CA3173732 A CA 3173732A CA 3173732 A CA3173732 A CA 3173732A CA 3173732 A1 CA3173732 A1 CA 3173732A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- compound
- prodrug
- pharmaceutically acceptable
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C07F9/306—Arylalkanephosphinic acids, e.g. Ar-(CH2)n-P(=X)(R)(XH), (X = O,S, Se; n>=1)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062983438P | 2020-02-28 | 2020-02-28 | |
| US62/983,438 | 2020-02-28 | ||
| US202063076113P | 2020-09-09 | 2020-09-09 | |
| US63/076,113 | 2020-09-09 | ||
| US202063117074P | 2020-11-23 | 2020-11-23 | |
| US63/117,074 | 2020-11-23 | ||
| US202163147982P | 2021-02-10 | 2021-02-10 | |
| US63/147,982 | 2021-02-10 | ||
| PCT/US2021/019973 WO2021174046A1 (en) | 2020-02-28 | 2021-02-26 | Gpr40 agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3173732A1 true CA3173732A1 (en) | 2021-09-02 |
Family
ID=77490353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3173732A Pending CA3173732A1 (en) | 2020-02-28 | 2021-02-26 | Gpr40 agonists |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230151037A1 (https=) |
| EP (1) | EP4110760A4 (https=) |
| JP (1) | JP2023528713A (https=) |
| CN (1) | CN115867536A (https=) |
| AU (1) | AU2021225966A1 (https=) |
| CA (1) | CA3173732A1 (https=) |
| TW (1) | TW202140424A (https=) |
| UY (1) | UY39106A (https=) |
| WO (1) | WO2021174046A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220150270A (ko) | 2019-10-07 | 2022-11-10 | 칼리오페, 인크. | Gpr119 효능제 |
| TW202140440A (zh) | 2020-02-28 | 2021-11-01 | 美商克力歐普股份有限公司 | Gpr40激動劑 |
| EP4337202A4 (en) | 2021-06-18 | 2025-04-02 | Aligos Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 |
| EP4448512A4 (en) | 2021-12-16 | 2025-11-19 | Aligos Therapeutics Inc | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 |
| CN118724767A (zh) * | 2023-03-28 | 2024-10-01 | 南京华狮新材料有限公司 | 一种氨基酸衍生物及其制备方法和作为中间体合成l-草铵膦的方法 |
| CN116178281B (zh) * | 2023-04-27 | 2023-07-21 | 中国药科大学 | 一种双功能免疫抑制剂及其制备方法和应用 |
| WO2025136929A1 (en) * | 2023-12-19 | 2025-06-26 | Kallyope, Inc. | Gpr40 agonists |
| WO2025137310A1 (en) * | 2023-12-22 | 2025-06-26 | Kallyope, Inc. | Crystalline gpr40 agonist and methods of making |
| WO2026019701A1 (en) * | 2024-07-15 | 2026-01-22 | Venenum Biodesign, LLC | Substituted phenylsulfonamides as mgat2 inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2558585C (en) * | 2004-02-27 | 2010-10-12 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders |
| JP4875978B2 (ja) * | 2004-03-15 | 2012-02-15 | 武田薬品工業株式会社 | アミノフェニルプロパン酸誘導体 |
| US8119617B2 (en) * | 2006-08-23 | 2012-02-21 | Novartis Ag | aSMase inhibitors |
| RU2627703C2 (ru) * | 2010-07-23 | 2017-08-10 | Конекшис Лайф Сайенсиз Пвт. Лтд. | Агонисты gpr40 |
| WO2013122028A1 (ja) * | 2012-02-13 | 2013-08-22 | 武田薬品工業株式会社 | 芳香環化合物 |
| EP3076959B1 (en) * | 2013-12-04 | 2018-07-04 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| WO2015119899A1 (en) * | 2014-02-06 | 2015-08-13 | Merck Sharp & Dohme Corp. | Antidiabetic compounds |
| TW201613878A (en) * | 2014-07-09 | 2016-04-16 | Janssen Pharmaceutica Nv | Pyrazine GPR40 agonists for the treatment of type II diabetes |
| US20220226298A1 (en) * | 2019-05-29 | 2022-07-21 | Kallyope, Inc. | Gpr40 agonists |
-
2021
- 2021-02-26 WO PCT/US2021/019973 patent/WO2021174046A1/en not_active Ceased
- 2021-02-26 CN CN202180031973.XA patent/CN115867536A/zh active Pending
- 2021-02-26 CA CA3173732A patent/CA3173732A1/en active Pending
- 2021-02-26 JP JP2022551555A patent/JP2023528713A/ja active Pending
- 2021-02-26 AU AU2021225966A patent/AU2021225966A1/en not_active Abandoned
- 2021-02-26 TW TW110106878A patent/TW202140424A/zh unknown
- 2021-02-26 EP EP21759537.0A patent/EP4110760A4/en not_active Withdrawn
- 2021-02-28 US US17/802,910 patent/US20230151037A1/en not_active Abandoned
- 2021-03-01 UY UY0001039106A patent/UY39106A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021174046A1 (en) | 2021-09-02 |
| AU2021225966A1 (en) | 2022-09-15 |
| TW202140424A (zh) | 2021-11-01 |
| CN115867536A (zh) | 2023-03-28 |
| EP4110760A4 (en) | 2024-09-18 |
| JP2023528713A (ja) | 2023-07-06 |
| EP4110760A1 (en) | 2023-01-04 |
| US20230151037A1 (en) | 2023-05-18 |
| UY39106A (es) | 2021-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3173732A1 (en) | Gpr40 agonists | |
| JP7745559B2 (ja) | Gpr40アゴニスト | |
| EP3976576A1 (en) | Gpr40 agonists | |
| CN114945560B (zh) | Gpr119激动剂 | |
| RS67682B1 (sr) | Jedinjenja ciklopropil-amida kao dvostruki inhibitori lsd1/hdac | |
| WO2021113363A1 (en) | Sstr5 antagonists | |
| WO2021236617A1 (en) | Ampk activators | |
| TW202543613A (zh) | 作為glp-1r激動劑的新型化合物及其用途 | |
| HK40085449A (en) | Gpr40 agonists | |
| WO2025136929A1 (en) | Gpr40 agonists | |
| HK40085450A (en) | Gpr40 agonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250826 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20251027 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260202 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260409 |